Company intelligence / Profile preview

T3 Productions and Consulting

Allschwil, Basel-Landschaft, Switzerlandmaterialplus.io ↗

Ownership: Private
Development stage: Other

Overview

T3 Pharmaceuticals developed a proprietary live bacterial platform to deliver therapeutic proteins directly into solid tumors. Their lead candidate, T3P-Y058-739, entered Phase 1 clinical trials for solid tumor treatment. The approach leverages engineered bacteria that selectively accumulate in tumors and secrete immunomodulatory proteins to stimulate anti-tumor immune responses. The company was acquired by Boehringer Ingelheim in November 2023 for up to CHF 450 million.

Therapeutic areas: Oncology
Modalities: Live biotherapeutic product therapyProtein
Industry: Biotech

Partnerships

BaseLaunch startup accelerator/incubator support during launch phase

Beyond the preview

Go deeper on T3 Productions and Consulting.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3 Productions and Consulting.

Explore the full profile